Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex.

Zhai Y, George CA, Zhai J, Nisenbaum ES, Johnson MP, Nisenbaum LK.

Neuropsychopharmacology. 2003 Jan;28(1):45-52.

2.

Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors.

Gewirtz JC, Chen AC, Terwilliger R, Duman RC, Marek GJ.

Pharmacol Biochem Behav. 2002 Sep;73(2):317-26.

PMID:
12117585
3.

Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.

Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK.

J Pharmacol Exp Ther. 2000 Jan;292(1):76-87.

PMID:
10604933
4.
6.

Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice.

Molinaro G, Traficante A, Riozzi B, Di Menna L, Curto M, Pallottino S, Nicoletti F, Bruno V, Battaglia G.

Mol Pharmacol. 2009 Aug;76(2):379-87. doi: 10.1124/mol.109.056580. Epub 2009 May 13.

PMID:
19439499
7.

Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice.

Kłodzinska A, Bijak M, Tokarski K, Pilc A.

Pharmacol Biochem Behav. 2002 Sep;73(2):327-32.

PMID:
12117586
8.

Pre-treatment with the mGlu2/3 receptor agonist LY379268 attenuates DOI-induced impulsive responding and regional c-Fos protein expression.

Wischhof L, Koch M.

Psychopharmacology (Berl). 2012 Jan;219(2):387-400. doi: 10.1007/s00213-011-2441-y. Epub 2011 Aug 24.

PMID:
21863235
10.

Activation of group II metabotropic glutamate receptors induces long-term depression of excitatory synaptic transmission in the substantia nigra pars reticulata.

Johnson KA, Niswender CM, Conn PJ, Xiang Z.

Neurosci Lett. 2011 Oct 24;504(2):102-106. doi: 10.1016/j.neulet.2011.09.007. Epub 2011 Sep 16.

11.

N-acetylcysteine modulates hallucinogenic 5-HT(2A) receptor agonist-mediated responses: behavioral, molecular, and electrophysiological studies.

Lee MY, Chiang CC, Chiu HY, Chan MH, Chen HH.

Neuropharmacology. 2014 Jun;81:215-23. doi: 10.1016/j.neuropharm.2014.02.006. Epub 2014 Feb 15.

PMID:
24534112
12.

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.

Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E.

Mol Pharmacol. 2007 Aug;72(2):477-84. Epub 2007 May 25.

PMID:
17526600
13.

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).

Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD.

J Pharmacol Exp Ther. 2007 Apr;321(1):308-17. Epub 2007 Jan 4.

PMID:
17204749
15.

Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain.

Di Liberto V, Bonomo A, Frinchi M, Belluardo N, Mudò G.

Neuroscience. 2010 Feb 3;165(3):863-73. doi: 10.1016/j.neuroscience.2009.11.012. Epub 2009 Nov 10.

PMID:
19909793
16.

DOI-Induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons.

Scruggs JL, Patel S, Bubser M, Deutch AY.

J Neurosci. 2000 Dec 1;20(23):8846-52.

17.
18.
20.

Supplemental Content

Support Center